ReviewClinical & experimental metastasis1999
Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.
Review in Clinical & experimental metastasis, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 46 citations in OpenAlex.
- Weichang'an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer-Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1.Frontiers in pharmacology · 2020Article
- Preclinical Pharmacokinetics of C118P, a Novel Prodrug of Microtubules Inhibitor and Its Metabolite C118 in Mice, Rats, and Dogs.Molecules (Basel, Switzerland) · 2018Article
- Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study.Open medicine (Warsaw, Poland) · 2018Article
- Biomarkers in preclinical cancer imaging.European journal of nuclear medicine and molecular imaging · 2015Review
- Blood oxygen level dependent angiography (BOLDangio) and its potential applications in cancer research.NMR in biomedicine · 2012Article
- Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.Current medicinal chemistry · 2010Article
- Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis.FEBS letters · 2007Article
- Molecular basis of angiogenesis and cancer.Oncogene · 2003Review
- Thalidomide in cancer treatment: a potential role in the elderly?Drugs & aging · 2002Review
- Angiogenesis-dependent diseases and angiogenesis therapy.Pathology oncology research : POR · 2001Review
- Angiogenesis as a target for breast cancer therapy.Journal of mammary gland biology and neoplasia · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis is the development of new blood vessels from the existing vascular bed. In normal conditions this tightly regulated process occurs only during embryonic development, the female reproductive cycle and wound repair. In contrast, in pathological conditions such as malignant growth, atherosclerosis and diabetic retinopathy, angiogenesis becomes persistent due to an imbalance in the interplay between the positive and negative regulatory signals controlling the process. Thus, the control of tumor neovascularization may lead to new therapeutic approaches. Indeed, several anti-angiogenic drugs are currently undergoing preclinical characterization and/or clinical investigation. Recent achievement has clarified the mechanisms of action leading to pathological angiogenesis and has highlighted the role of hypoxia, growth factors, growth factor-receptors, enzymes and cell adhesion molecules involved in the process. This knowledge has permitted the design of receptor antagonists, adhesion molecule blockers and new targeted vascular approaches including gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.